EP3 Stock Overview
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OraSure Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.92 |
| 52 Week High | US$7.50 |
| 52 Week Low | US$3.92 |
| Beta | 0.18 |
| 1 Month Change | -15.17% |
| 3 Month Change | -30.70% |
| 1 Year Change | -23.72% |
| 3 Year Change | -36.74% |
| 5 Year Change | -37.99% |
| Change since IPO | -11.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| EP3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -5.0% | -2.0% |
| 1Y | -23.7% | -13.6% | -0.3% |
Return vs Industry: EP3 underperformed the German Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: EP3 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| EP3 volatility | |
|---|---|
| EP3 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EP3's share price has been volatile over the past 3 months.
Volatility Over Time: EP3's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 638 | Carrie Eglinton Manner | www.orasure.com |
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services.
OraSure Technologies, Inc. Fundamentals Summary
| EP3 fundamental statistics | |
|---|---|
| Market cap | €379.25m |
| Earnings (TTM) | €50.37m |
| Revenue (TTM) | €380.66m |
7.6x
P/E Ratio1.0x
P/S RatioIs EP3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EP3 income statement (TTM) | |
|---|---|
| Revenue | US$405.47m |
| Cost of Revenue | US$226.05m |
| Gross Profit | US$179.42m |
| Other Expenses | US$125.77m |
| Earnings | US$53.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 44.25% |
| Net Profit Margin | 13.23% |
| Debt/Equity Ratio | 0% |
How did EP3 perform over the long term?
See historical performance and comparison